 |
 |
Therapeutic
|
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
| Title |
|
Fierce Competition for a Shrinking HCV Market? |
|
| Sub title |
|
|
|
| Author |
|
BioSeeker |
|
| Publication date |
|
October 2002 |
|
| ISBN |
|
n/a |
|
| Pages |
|
50 |
|
| Price |
|
pdf £420 | print £450 |
 |
 |
Summary
Hepatitis C virus (HCV) has already caused a global epidemic, but the worst may yet be to come. According to the CDC nearly 4 million people are or have been infected with HCV in the U.S. alone. Of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade.
The number of new infections per year, however, has declined from an average of 240,000 in the 1980s to about 25,000 in 2001. By 2020 almost all of the infected will have had the disease for more than 25 years. Between the years 2010 and 2020, most patients will then have reached an age of 55 to 75 years, many infected will die of other reasons before they will be diagnosed and started any anti-HCV therapy.
In this Highlight Report, BioSeeker has focused on three classes of therapeutic approaches as they represent different therapeutic strategies, but also as they target different time spans in the HCV market: immunomodulating substances, protease inhibitors, and vaccines. There is still a strong interest in developing new immunomodulating therapies for HCV despite the promise of the pegylated interferons. There is also increasing enthusiasm for targeting HCV molecular products such as protease inhibitors. The understanding of hepatitis C at a molecular level has also opened the door for more targeted development of a prophylactic or therapeutic HCV vaccine. The report analyzes the short, mid-range and long-term market development by studying three different therapeutic approaches in different developmental stages.
Several large pharmaceutical companies are conducting R&D related to HCV, but with different focus. BioSeeker Group tries to assess the competition between these therapeutic strategies and to correlate this with possible market development. Due to the high competition and a shrinking market some therapies will have difficulties to reach sufficient revenues within their lifecycle. Activities from a total of 50 companies are described.
Companies included in the report:
Agouron, ALZA, Amarillo, Anadys, Axys, BioMedicines, Biopharm Group, BioVex, Boehringer Ingelheim, Bristol Myers Squibb, Chiron, Corvas, Dimethaid, Dynavax Technologies, Eli Lilly, Enzo, Epimmune, Eurodiagnostica, Fumapharm, Genencor, GeneTrol, GenPhar, GlaxoSmithKline, Hawaii Biotech Group, Human Genome Sciences, ICN Pharm., Immusystems, Inhale Thera., Innogenetics, InterCell, InterMune, Lexicon Genetics, Maxim Pharmaceuticals, Medivir, Merck, Metaphore Pharmaceuticals, Oxo Chemie, Pepgen Corp., Pharming, Phogen, Roche, Schering-Plough, SciClone, Toray Industries, Triangle Pharmaceuticals, Tripep, Vernalis, Vertex, Viragen, XTL Biopharmaceuticals
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 TABLE OF CONTENTS |
 |
Content
Executive Summary
Introduction
HCV Incidence from 240 000 to 25 000 in 20 Years
Figure 1 – Decreasing HCV Incidence
Figure 2 – Decreasing HCV Prevalence
Intravenous Transmission
A Growing Market in the Short Term
Figure 3 – HCV Market Size Estimations
Current Treatment Older than the Virus
Drug Development Obstacles and Promises
Current Treatments - A Duel Between 2 Companies
Genotype 1 Prevalent and Resistant
Interferon Yielding Modest Sustained Virological Response
Pegylation Improves Efficacy and Administration
The Launch of Generic Ribavirin
Combination Therapy Cures Half of the Patients
An Anti-HCV collaborative cluster
Figure 4 - Collaborative cluster
Disturbing Side Effects
Will Future Treatments Be Revolutionizing?
ImmunoModulators - Capitalizing the Immediate Opportunity
Company Activity: Big Pharma & Small Biotech
Triangle Drama in Human Lactoferrin R&D
Viragen in a Central Role for Success?
New Drug Delivery for Interferon
InterMune Well Seated?
Recombinant Fusion Protein up for Proof
Combinatory Treatment With 3 Drugs
A Long Line of Company Collaborations Tie Immunomodulars Together
Figure 5 - Zandaxin Increases Resopnse Rates
Alternative To Ribavirin
Protease Inhibitors - A Molecular Approach
Small-molecule inhibitors
Peptide-based inhibitors
NS4A inhibitors
Macromolecular inhibitors
Company Activity: At Least 6 of the Big Pharma
Prophylactic Vaccines Eradicating HCV?
Research Retrospect
Company Activity: Almost 20 Companies with interest in HCV Vaccines
Connection of Companies building the Core of Genencor's Strength
Will Innogenetics be First With a Vaccine?
Box 1 Results from Innogenetics Phase II clinical trial
A Strong Alliance in the DNA Vaccine Business
Conclusions: Has the Train Already Passed?
Table 1 – Competitive Evaluation of Short, Medium and Long Term Therapeutics for the HCV Market
Figure 6 - Summary of analytical conclusions
Index
|
|
|
|
Therapeutic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
| No additional author information available for this product |
|
|
|
|
|
